

Nivolumab CheckMate 649

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Nivolumab CheckMate 649

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

1



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: First-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma

Experimental Arm: Nivolumab + Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX)

Control Arm: ChT (FOLFOX or CAPOX)



